Asia Pacific Biologics Market Size & Outlook, 2024-2030
Asia Pacific biologics market, 2018-2030 (US$M)
Related Markets
Asia Pacific biologics market highlights
- The Asia Pacific biologics market generated a revenue of USD 59,964.4 million in 2024.
- The market is expected to grow at a CAGR of 10.7% from 2025 to 2030.
- In terms of segment, monoclonal antibodies (mabs) was the largest revenue generating product in 2024.
- Antisense & RNAi Therapeutics is the most lucrative product segment registering the fastest growth during the forecast period.
Asia Pacific data book summary
| Market revenue in 2024 | USD 59,964.4 million |
| Market revenue in 2030 | USD 110,546.4 million |
| Growth rate | 10.7% (CAGR from 2025 to 2030) |
| Largest segment | Monoclonal antibodies (mabs) |
| Fastest growing segment | Antisense & RNAi Therapeutics |
| Historical data covered | 2018 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Monoclonal antibodies (MABs), Vaccines, Recombinant Proteins, Antisense & RNAi Therapeutics |
| Key market players worldwide | Samsung BioLogics, Amgen Inc, Novo Nordisk A/S ADR, AbbVie Inc, Sanofi SA, Johnson & Johnson, Celltrion Healthcare, Bristol-Myers Squibb Co, Eli Lilly and Co, Roche Holding AG ADR |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 15.0% of the global biologics market in 2024.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 110,546.4 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Biologics Market Scope
Biologics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Asia Pacific biologics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biologics market will help companies and investors design strategic landscapes.
Monoclonal antibodies (mabs) was the largest segment with a revenue share of 69% in 2024. Horizon Databook has segmented the Asia Pacific biologics market based on monoclonal antibodies (mabs), vaccines, recombinant proteins, antisense & rnai therapeutics covering the revenue growth of each sub-segment from 2018 to 2030.
The Asian biologics industry is growing at a lucrative pace and is expected to emerge as the fastest-growing country owing to factors such as regulatory changes, improved infrastructure, and the presence of a large number of patients.
These regulatory changes are aimed at alignment with clinical research activity and accelerating drug approvals. Moreover, growth in the number of clinical studies conducted in the region has contributed in helping regulatory authorities with an improved understanding of the development of healthcare products.
Furthermore, the fact that conducting clinical trials in countries such as India is relatively less expensive compared to western countries has also contributed in the migration of several biologic developing companies towards this region.
Reasons to subscribe to Asia Pacific biologics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Asia Pacific biologics market databook
-
Our clientele includes a mix of biologics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific biologics market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific biologics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Asia Pacific Biologics Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
